GGrantIndex
Sort

48,018 grants matching immunotherapy

Co-Clinical Research Resource for Imaging Tumor Associated Macrophages

$652,560
Heike Elizabeth Daldrup-Link · Stanford University · U24 · FY2021 · CA

Cerebral amyloid angiopathy fluid biomarkers evaluation (CAFE)

$652,534
William E. Van Nostrand · University Of Rhode Island · R01 · FY2019 · NS

Accelerating Multi-modal Biomarker Discovery in Translational Research with Cloud Data Integration

$652,516
David Craford · Cytobank, Inc. · R44 · FY2019 · GM

Co-Clinical Research Resource for Imaging Tumor Associated Macrophages

$652,473
Heike Elizabeth Daldrup-Link · Stanford University · U24 · FY2025 · CA

Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer

$652,414
Nupam P Mahajan · Washington University · R01 · FY2024 · CA

Single Cell Analysis of the Infiltrative Margins of Glioblastoma and Post Treatment Recurrence

$652,348
Jeffrey N Bruce · Columbia University Health Sciences · R01 · FY2023 · NS

Innate Immunity Stimulation via CpG ODN in a Non-Human Primate Model of Sporadic Cerebral Amyloid Angiopathy

$652,338
Henrieta Scholtzova · New York University School Of Medicine · R01 · FY2020 · NS

Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer

$652,287
Daniel J. Powell · University Of Pennsylvania · R01 · FY2023 · CA

Sex Differences in NK Cells Mediated by X-linked UTX

$652,282
Maureen A Su · University Of California Los Angeles · R01 · FY2023 · AI

Sustaining antitumor effector CD8+ T cells for cancer therapy

$652,206
Bin Zhang · Northwestern University At Chicago · R01 · FY2025 · CA

The role of brain resident T cells in Alzheimer's disease

$652,205
Pamela Rosato · Dartmouth College · R01 · FY2023 · AG

The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy

$652,200
Jennifer M Munson · Virginia Polytechnic Inst And St Univ · R01 · FY2025 · NS

Dissecting the role of CD8+ T cells in atherosclerosis

$652,158
Chiara Giannarelli · New York University School Of Medicine · R01 · FY2024 · HL

Antigen-specific ‘kick and kill’ of the latent HIV reservoir using dendritic cells

$652,156
Robbie B Mailliard · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · AI

MR-Guided Focused Ultrasound Combined with Immunotherapy to Treat Malignant Brain Tumors

$652,022
Max Wintermark · Stanford University · R01 · FY2017 · CA

Image-guided ultrasound therapy and drug delivery in pancreatic cancer

$652,017
Katherine W Ferrara · Stanford University · R01 · FY2018 · CA

Cancer Pharmacology

$651,936
Lorraine J Gudas · Weill Medical Coll Of Cornell Univ · T32 · FY2022 · CA

Development of therapeutic chemokine-based formulations

$651,880
Bira Arya · National Institute On Aging · ZIA · FY2015 · AG

Gut Microbiome and Cancer Immunotherapy Outcomes in Advanced Renal Cell Carcinoma

$651,814
Veronika Fedirko · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Central and peripheral immune cross-talk in Alzheimer's disease and their modulation by a novel immunotherapy

$651,539
Alireza Faridar · Methodist Hospital Research Institute · R01 · FY2023 · AG

Central and peripheral immune cross-talk in Alzheimer's disease and their modulation by a novel immunotherapy

$651,539
Alireza Faridar · Methodist Hospital Research Institute · R01 · FY2024 · AG

Biology of R-Spondin-Induced Sensitization to Asparaginase in Colorectal Cancer

$651,421
Alejandro Gutierrez · Boston Children'S Hospital · R01 · FY2021 · CA

Novel Health Equity Intervention to Improve Pediatric Oncology Outcome Disparities: Targeting Poverty and Psychosocial Stress

$651,395
Kira O. Bona · Dana-Farber Cancer Inst · R01 · FY2022 · CA

ENHANCEMENT OF BIOMARKERS FOR TYPE 1 DIABETES

$651,363
Mark A Herman · Baylor College Of Medicine · R01 · FY2021 · DK

A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma

$651,354
Stuart J Kahn · Syntrix Biosystems, Inc. · R44 · FY2021 · CA